BirchBioMed (BRBM) investor relations material

Company overview and business model

• Clinical-stage biopharmaceutical company focused on anti-scarring (fibrosis), autoimmune diseases, and organ fibrosis therapies.

• Holds exclusive, worldwide, non-perpetual pharmaceutical licenses from UBC for FS1/FS2 and AI-001 technologies.

• Lead product FS2 (kynurenic acid) targets severe burns, organ fibrosis, and scarring; AI-001 targets type 1 diabetes (T1D) and alopecia areata (AA).

• Monetization strategy includes out-licensing or sale of its NHP/Cosmetics Platform and reinvestment into Rx development.

Financial performance and metrics

• No revenue generated to date; net losses of $4.55M (2025), $3.36M (2024), and $0.54M (Q1 2026).

• Cash and cash equivalents of $3.19M as of March 31, 2026; working capital of $2.62M.

• Accumulated deficit of $25.15M as of March 31, 2026.

• Operating expenses primarily for R&D and G&A; R&D focused on burns, IPF, T1D, and AA.

• Convertible notes of $9.08M converted to equity in February 2026; no outstanding convertible notes as of the filing.

Use of proceeds and capital allocation

• Company will not receive proceeds from the direct listing; proceeds from any out-licensing or sale of NHP/Cosmetics Platform to be reinvested in Rx development.

• Ongoing need to raise additional capital to fund operations and clinical trials over the next 12 months.